Journal article

Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial.

Edmond M Kwan, Lavinia Spain, Angelyn Anton, Chun L Gan, Linda Garrett, Deborah Chang, Elizabeth Liow, Caitlin Bennett, Tiantian Zheng, Jianjun Yu, Chao Dai, Pan Du, Shidong Jia, Heidi Fettke, Claire Abou-Seif, Gargi Kothari, Mark Shaw, Phillip Parente, Carmel Pezaro, Ben Tran Show all

Eur Urol | Published : 2021


BACKGROUND: Immune checkpoint inhibitor monotherapy in metastatic castration-resistant prostate cancer (mCRPC) has produced modest results. High-dose radiotherapy may be synergistic with checkpoint inhibitors. OBJECTIVE: To evaluate the efficacy and safety of the PD-L1 inhibitor avelumab with stereotactic ablative body radiotherapy (SABR) in mCRPC. DESIGN, SETTING, AND PARTICIPANTS: From November 2017 to July 2019, this prospective phase 2 study enrolled 31 men with progressive mCRPC after at least one prior androgen receptor-directed therapy. Median follow-up was 18.0 mo. INTERVENTION: Avelumab 10 mg/kg intravenously every 2 wk for 24 wk (12 cycles). A single fraction of SABR (20 Gy) was ad..

View full abstract